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To determine risk for drug-resistant malaria parasites 
entering Madagascar from Comoros Islands, we screened 
travelers. For the 141 Plasmodium falciparum isolates de-
tected by real-time PCR, frequency of mutant alleles of 
genes associated with resistance to chloroquine and pyri-
methamine was high. International-level antimalarial policy 
and a regional antimalarial forum are needed.
I
n the southwestern Indian Ocean, the epidemiologic 
features of malaria and antimalarial drug resistance dif-
fer considerably between islands that are very close geo-
graphically. Malaria remains a major public health prob-
lem in Madagascar and the Comoros Islands, whereas the 
situation is different on other nearby islands. Chloroquine 
resistance ranges from moderate in Madagascar (1–3) to 
high in the Comoros Islands (4,5), whereas pyrimethamine 
resistance is absent in Madagascar (3,6) but present at high 
levels in the Comoros Islands (5). The paradoxical situa-
tion of resistance to antimalarial drugs and prevalence of 
mutant-type parasites (for the Plasmodium  falciparum 
chloroquine resistance transporter [pfcrt] gene, 90% of 76T 
alleles in the Comoros Islands vs. 3% in Madagascar; for 
the P. falciparum dihydrofolate reductase [dhfr] gene, 69% 
of 108N alleles in the Comoros Islands vs. 0% in Madagas-
car) (2,5,7) in such close geographic proximity led us to 
perform this study.
Historically, the Comoros Islands and Madagascar 
have been linked by human travel, and the importation of 
pathogens has already been documented, in the cholera 
epidemic of 1998–1999 (8) and in more recent outbreaks 
of arbovirus infection (9,10). Most travel between the Co-
moros Islands and Madagascar occurs through the seaport 
and airport of Mahajanga, the main city on the northwest-
ern coast of Madagascar. To improve the monitoring of an-
timalarial drug resistance in Madagascar, we assessed the 
frequency of P. falciparum mutant alleles of genes associ-
ated with resistance to chloroquine (pfcrt and P. falciparum 
multidrug resistance 1 [pfmdr-1] gene) and pyrimethamine 
(dhfr) among travelers entering Madagascar from the Co-
moros Islands.
The Study
The study was performed from March to July 2006, in 
the seaport and the airport of Mahajanga, on the northwest 
coast of Madagascar (Figure 1). These sites are the main 
communications crossroads between the Comoros Islands 
and Madagascar. The study was approved by the National 
Ethics Committee of the Ministry of Health and Family 
Planning of Madagascar.
All travelers from the Comoros Islands who consented 
to participate on arrival in Madagascar, regardless of their 
age, sex, nationality, and presence or absence of symptoms, 
were enrolled in the study. For each participant, , a ques-
tionnaire was ﬁ  lled out and a ﬁ  nger-prick blood sample was 
collected. Rapid diagnostic tests (OptiMAL-IT, DiaMed 
AG, Cressier sur Morat, Switzerland) and thick/thin blood 
smears were performed in the ﬁ  eld. Patients with a positive 
rapid test result were promptly treated with an artesunate 
and amodiaquine combination (Arsucam, Sanoﬁ  -Aventis, 
Paris, France), according to Madagascar’s national malaria 
policy.
Thick/thin blood smears were stained and analyzed by 
an experienced technician, without reference to rapid test 
results. A minimum of 200 consecutive ﬁ  elds were counted 
for each thick blood ﬁ  lm before a slide was classiﬁ  ed as 
negative. The number of parasites in thick blood ﬁ  lms was 
determined per 200 or 500 leukocytes, assuming 8,000 leu-
kocytes/μL of blood. Thin blood smears were also exam-
ined for other Plasmodium spp.
Parasite DNA was extracted from blood samples by 
using the phenol/chloroform method. P. falciparum carri-
ers were detected by real-time PCR in a RotorGene 3000 
thermocycler (Corbett Life Science, Sydney, New South 
Wales, Australia), as described by Mangold et al. (11). 
PCR and restriction fragment length polymorphism analy-
ses were performed for 3 genes (codon 108 of dhfr, co-
don 76 of pfcrt, and codon 86 of pfmd-1) for the detection 
of mutant alleles. (Detailed descriptions of these methods 
are available from http://medschool.umaryland.edu/cvd/
plowe.html.) Laboratory strains of P. falciparum were 
used as controls (positive and negative) and included in 
all PCR and enzyme digestion procedures (DNA from the 
W2, HB3, and 3D7 reference strains from the Malaria Re-
search and Reference Reagent Resource Center, Division 
of Microbiology and Infectious Diseases, National Insti-
tute of Allergy and Infectious Disease, National Institutes 
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of Health, Manassas, VA, USA). Statistical analyses were 
performed by using SPSS software (SPSS Inc., Chicago, 
USA). Odds ratios were calculated from logistic regression 
parameter estimates, and p values were determined with the 
signiﬁ  cance level set at p<0.05.
Among the 1,130 travelers registered on arrival in 
Mahajanga, 947 agreed to participate in the study (crude 
participation rate 83.8%). The baseline characteristics of 
the enrolled travelers are given as a function of nationality 
(Comorian or Malagasy) in the Table. The frequency of P. 
falciparum carriers was 0.5% (5/947) according to rapid di-
agnostic test, 3.2% (30/947) according to microscopy, and 
14.9% (141/947) according to real-time PCR.
For the 141 P. falciparum isolates detected by real-
time PCR, the frequency of the mutant alleles of genes as-
sociated with resistance to chloroquine (pfcrt and pfmdr-1) 
and pyrimethamine (dhfr) was 80.1% (113/141) for the 76T 
mutant allele of the pfcrt gene, 99.3% (140/141) for the 86Y 
mutant allele of the pfmdr-1 gene, and 95.0% (134/141) for 
the 108N allele of the dhfr gene. More detail is provided 
in the Table. Univariate analysis of risk factors associated 
with the carriage of P. falciparum mutant alleles showed 
that for Comorian travelers, only a history of travel in Af-
rica in the past 3 months was identiﬁ  ed as signiﬁ  cant (odds 
ratio 2.29, 95% conﬁ  dence interval 1.27–4.13, p<0.01). We 
used these data to generate a map assessing the potential 
risk for the spread of P. falciparum mutant-type alleles in 
Madagascar (Figure 2).
Conclusions
Despite some methodologic limitations (limited study 
period, limited number of passengers screened, taking into 
account only registered travelers), this study provides the 
ﬁ   rst, to our knowledge, direct measurement of parasite 
movement between the Comoros Islands and Madagas-
car. This study thus enables an assessment of the potential 
threat of P. falciparum mutant allele parasites being intro-
duced into Madagascar. 
First, we noted that for detection of P. falciparum car-
riers, real-time PCR was 4.6 times more sensitive than mi-
croscopy and 30 times more sensitive than rapid diagnostic 
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Figure 1. Regional map of the Indian Ocean, showing A) location of Comoros Islands and Madagascar; B) Comoros Islands; and C) 
location of Mahajanga seaport and airport, Madagascar.
Figure 2. Map assessing the potential risk for spread of Plasmodium 
falciparum mutant-type alleles associated with resistance to 
chloroquine and pyrimethamine from the Comoros Islands to 
Madagascar, Mahajanga, Madagascar, 2006.Drug-Resistant Malaria Parasites, Madagascar
testing based on parasite lactate dehydrogenase detection, 
according to the threshold detection level of the techniques 
used (11,12). The results suggest that most of the P. falci-
parum carriers had low-level parasitemia. Second, most of 
the imported parasites carried resistance-associated muta-
tions, consistent with the frequency of mutant forms of P. 
falciparum circulating in the Comoros Islands (4,5). Third, 
according to the places in which the Comorian travelers 
stayed and the places in which the Malagasy travelers 
lived, the potential area of antimalarial drug–resistant para-
site spread was located in the northwestern area, which has 
a transmission season of >6 months per year (13).
On the basis of our ﬁ  ndings, we suggest that antima-
larial drug policy should be formulated at an international, 
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Table. Baseline characteristics of enrolled travelers arriving in Mahajanga, Madagascar, from Comoros Islands, 2006*
Characteristic Comorian travelers, n = 662  Malagasy travelers, n = 285  p value 
Place of arrival, n (%) 
  Airport  553 (83.5)  148 (51.9) 
  Seaport  109 (16.5)  137 (48.1) 
<10
–6
Female 41% 29% <10
–3
Age
  Mean age in years (SD)  35.4 (14.7)  35.7 (12.5)  NS
 <5  y,  %  3.7 1.5 NS
Declared site of residence, % 
 Grande  Comore  65.2 NA
 Anjouan  31.2 NA
 Mohéli  3.6 NA
 Northwestern  Madagascar  NA 64.1
  Central Highlands Madagascar  NA 23.8
 North  Madagascar  NA 7.1
 East  Madagascar  NA 3.6
 Southwestern  Madagascar  NA 1.4
 Northeastern  Madagascar  NA 0.4
  Mean duration of stay in days (SD)  63.5 (146.8)  111.8 (300)  NS
Place of stay in Madagascar, % 
 Northwestern  Madagascar  65.1 NA
  Central Highlands Madagascar  32.0 NA
 North  Madagascar  1.9 NA
 East  Madagascar  0.5 NA
 Southwestern  Madagascar  0.5 NA
Place of stay in Comoros Islands, % 
 Grande  Comore  NA 79.3
 Anjouan  NA 20.3
 Mohéli  NA 0.4
Malaria symptoms at arrival, %†   3.3 3.9 NS
Medical history declared by travellers in the 3 previous months, % 
 Suspected  malaria  4.8 7.4 NS
 Confirmed  malaria  1.7 2.5 NS
  Treated with antimalarial drugs   4.5 7.4 NS
History of travel in past 3 months 
  In Africa, %  3.5% 4.9% NS
  In Asia, %  0.2% 3.9% NS
No. malaria-positive samples (%)  105 (74.5)  36 (25.5) 
Frequency of mutant alleles,‡ % 
 76T  82.0 75.0 NS
 86Y  100.0 97.2 NS
 108N  96.2 91.7 NS
  Triple mutant type, 76T-86Y-108N  82.2 71.4 NS
  Double mutant type 1, 76K-86Y-108N 14.4 17.8 NS
  Double mutant type 2, 76T-86Y-108S 2.2 3.6 NS
  Single mutant type, 76K-86Y-108S 1.1 3.6 NS
 Wild  type,  76T-86Y-108N  0 3.6 NS
*NS, not significant; NA, not applicable; boldface indicates mutant types. 
†Fever, headache, diarrhea, shivering, vomiting. 
‡Associated with resistance to chloroquine (pfcrt and pfmdr-1) and pyrimethamine (dhfr).  DISPATCHES
rather than a national, level. Given that the Malagasy gov-
ernment’s goal is moving toward malaria elimination, inter-
national considerations in antimalarial policy would avoid 
the possibility of a coherent national policy being annulled 
by mutations originating in or spreading through neighbor-
ing countries. For example, the introduction of high-level 
chloroquine or pyrimethamine resistance from the Co-
moros Islands could compromise the use of the artesunate 
and amodiaquine combination as a ﬁ  rst-line treatment for 
uncomplicated falciparum malaria or the use of sulfadox-
ine-pyrimethamine for intermittent preventive treatment in 
pregnant women and render these strategies useless.
In conclusion, we suggest the creation, as soon as pos-
sible, of a regional antimalarial forum in the Indian Ocean, 
similar to the East African Network for Monitoring An-
timalarial Treatment (www.eanmat.org). Such a forum 
would enable the countries of the region to share national 
information on antimalarial drug efﬁ  cacy, such as the prev-
alence of drug resistance molecular markers, and to debate 
proposed changes in national policy.
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